Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Thyroid Cancer, Papillary 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Pleuropulmonary blastoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphedema 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Duodenal Neoplasms 1Carcinoma, Lobular 1Anatomic Stage III Breast Cancer AJCC v8 1Anatomic Stage II Breast Cancer AJCC v8 1Adenocarcinoma, Follicular 1

Interventions

neratinib 1Sampling Studies 1Radiotherapy, Adjuvant 1Positron Emission Tomography Computed Tomography 1Mastectomy, Segmental 1Magnetic Resonance Spectroscopy 1Liquid Biopsy 1High-Energy Shock Waves 1Drug Therapy 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Lobular × High-Energy Shock Waves × Clear all
NCT05919108 2025-09-09

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
30 enrolled

Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡